Eagle Pharmaceuticals (NASDAQ:EGRX) Downgraded to “Hold” at BidaskClub

Eagle Pharmaceuticals (NASDAQ:EGRX) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Thursday, January 18th.

A number of other equities research analysts also recently weighed in on the company. ValuEngine upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Zacks Investment Research downgraded Eagle Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 9th. Piper Jaffray Companies restated a “buy” rating and set a $75.00 price objective on shares of Eagle Pharmaceuticals in a report on Friday, October 27th. Mizuho restated a “sell” rating and set a $37.00 price objective on shares of Eagle Pharmaceuticals in a report on Wednesday, November 8th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $75.00 target price (down previously from $81.00) on shares of Eagle Pharmaceuticals in a research report on Thursday, November 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. Eagle Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $63.67.

Shares of Eagle Pharmaceuticals (EGRX) opened at $59.39 on Thursday. Eagle Pharmaceuticals has a 12 month low of $45.05 and a 12 month high of $97.15. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.15 and a current ratio of 5.30. The company has a market capitalization of $868.59, a PE ratio of 9.56 and a beta of 1.25.

Hedge funds have recently bought and sold shares of the business. Schwab Charles Investment Management Inc. raised its stake in shares of Eagle Pharmaceuticals by 2.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 37,053 shares of the specialty pharmaceutical company’s stock valued at $2,924,000 after buying an additional 737 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Eagle Pharmaceuticals by 0.4% in the second quarter. Bank of New York Mellon Corp now owns 116,510 shares of the specialty pharmaceutical company’s stock valued at $9,191,000 after buying an additional 482 shares during the period. Legal & General Group Plc raised its stake in shares of Eagle Pharmaceuticals by 3.9% in the second quarter. Legal & General Group Plc now owns 14,984 shares of the specialty pharmaceutical company’s stock valued at $1,182,000 after buying an additional 563 shares during the period. BNP Paribas Arbitrage SA raised its stake in shares of Eagle Pharmaceuticals by 58.7% in the second quarter. BNP Paribas Arbitrage SA now owns 2,456 shares of the specialty pharmaceutical company’s stock valued at $194,000 after buying an additional 908 shares during the period. Finally, Principal Financial Group Inc. raised its stake in shares of Eagle Pharmaceuticals by 9.6% in the second quarter. Principal Financial Group Inc. now owns 67,990 shares of the specialty pharmaceutical company’s stock valued at $5,364,000 after buying an additional 5,954 shares during the period.

TRADEMARK VIOLATION WARNING: “Eagle Pharmaceuticals (NASDAQ:EGRX) Downgraded to “Hold” at BidaskClub” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/13/bidaskclub-lowers-eagle-pharmaceuticals-egrx-to-hold.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply